About
Learn how an emerging NAM is helping advance more efficient, human-relevant strategies for assessing thyroid hormone disruption while reducing reliance on animal testing.

Endocrine-disrupting chemicals present a growing global health concern, with the potential to interfere with critical hormonal systems such as thyroid function. However, current approaches to evaluating thyroid toxicity often rely on resource-intensive animal studies or in vitro methods that do not fully capture human-relevant biology.

In this webinar, Chad Deisenroth introduces advances in a new approach method (NAM) for thyroid toxicity testing, with a focus on a human-relevant in vitro model (Human 3D Thyroid Microtissue) that enables direct assessment of thyroid hormone synthesis.

Attendees will gain insight into how this model addresses key limitations in traditional testing strategies by improving biological relevance, reproducibility, and scalability. The session also highlights how recent validation efforts have strengthened confidence in this approach, supporting its application in screening workflows for endocrine-disrupting chemicals.

Key Topics:

  • Global Health Risk: Endocrine-disrupting chemicals are widespread and threaten human health by interfering with hormonal systems.

  • Screening Bottleneck: Current hazard identification relies on resource-intensive animal testing, which is too slow and costly to address the vast chemical landscape.

  • Innovative Solution: Human thyroid microtissues provide a faster, biologically relevant alternative for regulatory thyroid toxicity screening.

Presenter
1715088151-cce819d7a724bc25
Chad Deisenroth, PhD
Principal Laboratory Toxicologist, Center for Chemical Informatics and Screening, UL Research Institutes' Chemical Insights
Dr. Chad Deisenroth is a Principal Laboratory Toxicologist in the Center for Chemical Informatics and Screening at UL Research Institutes' Chemical Insights. He earned his Ph.D. in Genetics and Molecular Biology from the University of North Carolina at Chapel Hill and completed postdoctoral training in chemical safety sciences at The Hamner Institutes for Health Sciences.

Prior to joining UL Research Institutes, Dr. Deisenroth served as a principal investigator in the Center for Computational Toxicology and Exposure at the U.S. Environmental Protection Agency, where he advanced the development and application of in vitro new approach methods - or NAMs - for predictive toxicology. His work at the EPA centered on engineering human-relevant cell culture models and innovative testing approaches to improve the speed, reliability, and biological relevance of chemical hazard identification for human health effects.

Dr. Deisenroth has authored numerous peer‑reviewed publications in leading toxicology journals and received recognition for several high‑impact contributions in the field of in vitro toxicology. He has also led U.S. efforts to validate NAM technology in collaboration with international partners and currently contributes to an OECD working group focused on standardizing and implementing NAMs for endocrine toxicity testing.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Country / Region*
Job Title*
Organization / Company*
Organization Type*
Main Application Area(s)*
Toxicology/safety
DMPK/ADME
Discovery & Early Research
Preclinical / Development
Regulatory & Risk Assessment
Assay / Model Development
Environmental / Ecotoxicology
Formulation / Product Safety
Other (please specify):
How would you describe your adoption of non-animal methods (NAMs)?*
Actively using NAMs as primary approach
Using a mix of NAMs and animal models
Exploring NAMs (pilot stage)
Interested but not yet using NAMs
Not currently considering NAMs
Would you be interested in learning more about human-relevant in vitro thyroid models?*
Yes – request follow-up
Yes – send additional information
Maybe later
No
utm_bmcr_source
Registration Terms
This event is hosted by Scientist.com. By registering and participating, you acknowledge that your personal data will be processed by Scientist.com. You also agree to receive email communication from Scientist.com about this webinar and other programs of similar nature. The sponsor of this webinar is LifeNet Health LifeSciences; by registering and participating, you acknowledge that your data will be processed in accordance with LifeNet Health LifeSciences’ Privacy Policy. You will receive email communication from LifeNet Health LifeSciences about this webinar and programs of similar interest. You can withdraw your consent at any time from these communications.
Yes, I consent to the registration terms.*
Yes, I consent to the registration terms.*
We use BigMarker as our webinar platform. By clicking Register, you acknowledge that the information you provide will be transferred to BigMarker processing in accordance with their Terms of Service and Privacy Policy.